Forte Biosciences, Inc. (FBRX)

Market Cap	1.94B +861.0%
Revenue (ttm)	n/a
Net Income	-87.94M
EPS	-4.55
Shares Out	25.19M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	76.99
Day's Range	n/a
52-Week Range	10.11 - 77.20
Beta	2.64
Analysts	Hold
Price Target	73.80 (-4.14%)
Earnings Date	Aug 12, 2026

About FBRX

Forte Biosciences, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for autoimmune and autoimmune-related diseases. The company offers products, such as its lead product candidate FB102, a proprietary molecule with applications for celiac disease, vitiligo, and alopecia areata; and services, including the clinical development and management of its Phase 2 clinical trials. Forte Biosciences, Inc. was incorporated in 2007 and is based in Dallas, Texas. As of August 27, 2026, Forte Biosciences, Inc. operates as a subsidiary ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: FBRX
• Website: https://www.fortebiorx.com

Analyst Summary

According to 5 analysts, the average rating for FBRX stock is "Hold." The 12-month stock price target is $73.8, which is a decrease of -4.14% from the latest price.

Price Target

$73.8

(-4.14% downside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jan 1, 2000

Data Sources Report a data error